Abstract C6: Composite profiling of angiogenic factors using Bio-Plex Pro™ Human Cancer Biomarker Panel-I.

Abstract

Abstract Angiogenesis is a feature of over 50 different disease states. These include cancer, rheumatoid arthritis, cardiovascular diseases, diabetes and psoriasis. Methods developed to study these diseases are important tool to establish a model for testing potential therapeutics. These methods include both in vivo and in vitro assays. In vivo angiogenesis assays are considered to be the most informative because of the complex nature of vascular responses to test reagents and responses that no in vitro model can achieve. However in vivo assays can be expensive, laborious and require extensive training to perform. In contrast, in vitro assays can be carried out expeditiously, less costly and easier to interpret. Often, these in vitro assays provide maximum benefit when developed as a multivariate index assay where the data of multiple assays function to yield a composite result to interpret experimental studies. Using the Luminex xMAP technology, we have developed a multiplex Bio-Plex Pro™ Human Cancer Biomarker Panel I that employs a magnetic bead-based workflow to measure angiogenesis biomarkers in diverse matrices including serum, plasma, cell culture supernatant and many other sample types. In combination with the Bio-Plex® suspension array and the Bio-Plex Pro™ wash station, the multiplexing feature makes it possible to quantify the level of multiple angiogenesis targets in a single well of a 96-well microplate in just 3 hours, using as little as 12.5 μL of serum or plasma. The panel of 16 markers includes sEGFR, FGF basic, Follistatin, G-CSF, sHER2/neu, HGF, sIL-6Ra, Osteopontin, Leptin, PDGF-BB, PECAM-1, Prolactin, SCF, sTie-2, sVEGFR-1 and sVEGFR-2. These markers were selected because of their direct relevance to the pathogenesis of tumor-associated angiogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C6.